• Alcon (Huenenberg, Switzerland) reported the commercial launch outside the U.S. of the new +3.0 Add Power AcrySof ReSTOR Aspheric intraocular lens (IOL). This lens is an improvement to ReSTOR Aspheric platform which is designed for correcting presbyopia in cataract patients. Clinical trials showed that the +3.0 Add Power AcrySof ReSTOR aspheric IOL optimally manages light energy delivered to the retina regardless of the lighting situation to provide patients with high resolution image quality and minimal visual disturbances. At the three-month follow-up exam, 95% of patients had combined distance corrected visual acuities (near, intermediate and distance) of 20/40 or better. Alcon makes eye care products.

• CMS (St. Louis) reported the commercial launch of its new 4-D treatment planning solution, Focal4D. CMS says the solution provides a comprehensive suite of capabilities that support the visualization and utilization of 4-D image sets to create structures and review treatment options. With support for respiratory-correlated CT images, the robust toolset includes multiple viewing options such as cine and variable window formats and automated processes for creation of internal target volumes. CMS, an Elekta company, makes radiation treatment planning and workflow management products.

• Edwards Lifesciences (Irvine, California) has presented new data on the Edwards Sapien transcatheter heart valve with the Ascendra transapical delivery system. The SOURCE trial is designed to evaluate commercial use of the Sapien valve with a prescribed training and proctoring program. It is a registry of procedural and short-term clinical outcomes. The current data reflect 309 cases at hospitals in 12 European countries. Survival at 30 days was 88%. Edwards Lifesciences makes heart valves and hemodynamic monitoring products.

• Volcano (San Diego) reported the use of its VH IVUS in GlaxoSmithKline's IBIS-2 trial. In the study, Volcano's VH IVUS technology demonstrated and quantified compositional changes in atherosclerotic plaque that occurred over time. In IBIS-2, VH IVUS showed compositional changes in the placebo group that suggest continued progression of necrotic core despite standard of care therapy. Use of the Lp-PLA2 inhibitor, darapladib, plus standard-of-care therapy prevented this progression. VH IVUS is a catheter-based technology that creates colorized tissue maps of plaque composition in real time. The technology uses spectral analysis techniques to allow simplified interpretation of ultrasound images and provide detailed information on the composition of each patient's atherosclerotic plaques. The color VH images show four plaque component types: necrotic core, dense calcium, fibrous and fibro-fatty. Volcano makes intravascular ultrasound products.